Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
At present there is no validated prognostic tool for patients with resectable pancreatic
cancer (RPC) to determine how best to tailor individual therapy. This study is to see if
tumor features in blood and imaging prior to surgery correspond with tumor heterogeneity in
the specimen after surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute